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ASSOCIATION BETWEEN AN MHC CLASS II ALLELE AND CLEARANCE OF HEPATITIS B VIRUS 
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Abstract
 
Background.
 
The course of hepatitis B virus
(HBV) infection does not appear to be determined by vari-
ations in viral virulence and may be influenced by the host
immune response. We studied the distribution of human
leukocyte antigens in children and adult men in the Gam-
bia who spontaneously recovered from HBV infection as
compared with the distribution of these antigens in sub-
jects with persistent infection.
 
Methods.
 
In a two-stage, case–control study, we an-
alyzed the frequency of MHC class I antigens and class
II haplotypes in subjects with either transient or persistent
HBV infection. MHC class I typing was performed by
microlymphocytotoxicity assays. MHC class II typing was
performed with analysis of restriction-fragment–length
polymorphisms (RFLPs), supplemented by other tech-
niques.
 
Results.
 
In the first stage (the study of children up to
the age of 10 years), the RFLP pattern 25-1, which in-
cludes the class II allele 
 
HLA-DRB1
 
*
 
1302,
 
 was found in
58 of 218 subjects with transient HBV infection (26.6 per-
cent) and 30 of 185 subjects with persistent infection
(16.2 percent) (relative risk of carrying the 25-1 pattern in
the persistently infected group as compared with the tran-
siently infected group, 0.53; 95 percent confidence inter-
val, 0.32 to 0.90; P
 

 
0.012). In the second stage (the
study of adults), 
 
HLA-DRB1
 
*
 
1302
 
 was found in 50 of 195
subjects with transient HBV infection (25.6 percent) and
in 3 of 40 subjects with persistent infection (7.5 percent)
(relative risk, 0.24; 95 percent confidence interval, 0.04 to
0.80; P
 

 
0.012). The RFLP pattern 13-2, which includes
the class II allele 
 
DRB1
 
*
 
1301,
 
 was less frequent in chil-
dren with persistent infection than in those with transient
infection, an association that was neither confirmed nor
excluded by the data on adults. Possible associations
with HLA class I antigens found in children were not sup-
ported by the data on adults.
 
Conclusions.
 
The MHC class II allele 
 
DRB1
 
*
 
1302 
 
was
associated with protection against persistent HBV infec-
tion among both children and adults in the Gambia.
(N Engl J Med 1995;332:1065-9.)
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I
 
NFECTION with the hepatitis B virus (HBV) may re-
sult in a number of conditions ranging from asymp-
tomatic persistent carriage to fulminant hepatitis with
liver failure. Most infected people have acute hepatitis
during which the virus is eliminated. About 80 percent
of adults in West Africa have been infected with HBV,
and in about 15 percent of these persons the virus is
not cleared.
 
1
 
 Persistent HBV infection predisposes
patients to chronic liver disease and hepatocellular
carcinoma
 
2
 
; HBV-related hepatocellular carcinoma is
the leading cause of death among men of working age
in the Gambia.
 
3,4
 
The outcome of HBV infection does not appear to
be determined by variations in virulence among viral
strains. Instead, the course of the disease may be influ-
enced by the host immune response. Although a small
proportion of people with persistent infection have spe-
cific types of immunodeficiency, such as human immu-
nodeficiency virus (HIV) infection
 
5 
 
or agammaglobulin-
emia,
 
6
 
 the majority are not immunocompromised. In
West Africa, children under the age of 10 years acquire
HBV infection asymptomatically from older siblings or
playmates, although the mechanism of transmission is
unclear.
 
7,8
 
 Mother-to-child transmission such as that
seen in the Far East is rare. An immature immune sys-
tem, as seen in newborns, and the tolerance-producing
effects of the transplacental transfer of HBV e antigen
are unlikely to affect the outcome of infection.
Variations in immune response are often associated
with polymorphism of the major histocompatibility
complex (MHC). The role of the MHC phenotype in
the outcome of HBV infection has been examined, but
no firm conclusion has been reached.
 
9-13
 
 Many studies
have been only large enough (with 33 to 79 subjects
positive for hepatitis B surface antigen) to detect very
strong associations between the MHC phenotype and
the disease state. Most of these studies have used sero-
logic methods of MHC class II typing. Such methods
diminish sensitivity, because they assign a large number
of alleles to the same serologic specificity.
We compared the distribution of HLA antigens in
children and adults in the Gambia who spontaneously
recovered from HBV infection with the distribution of
antigens in those with persistent infection.
 
M
 
ETHODS
 
Study Subjects
 
The study subjects were all West Africans living in the western,
coastal region of the Gambia in the area surrounding the capital,
Banjul. Two different groups were recruited between 1988 and 1990
for two stages of the study. In the first stage, children up to 10 years
of age were recruited at the Royal Victoria Hospital, Banjul, and the
Medical Research Council (MRC) Hospital, Fajara, where they had
been seen for a variety of conditions unrelated to HBV. In the second
stage, adult men were recruited from among healthy blood donors.
Both groups had previously been studied as part of a case–control
study of susceptibility to malaria.
 
14
 
 Permission for the study was
granted by the Joint Ethics Committee, and the study was approved
by the Scientific Coordinating Committee. Consent for phlebotomy
was obtained from each child’s parent or guardian.
In both stages, the subjects were grouped according to the results
of serologic tests for HBV. People who had never been exposed to
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HBV were negative for antibodies against the HBV core antigen
(hereafter referred to as HBV core antibody). People who had spon-
taneously recovered from HBV infection were positive for IgG HBV
core antibody and negative for HBV surface antigen. People with per-
sistent HBV infection were positive for both HBV core antibody and
hepatitis B surface antigen. People with recent HBV infection who
may not have had sufficient opportunity to eliminate hepatitis B sur-
face antigen (i.e., those who were positive for that antigen and for IgM
HBV core antibody) were excluded from the analysis. One hundred
seven people who had been vaccinated against HBV were classified as
unexposed and were not included in the analysis of HLA frequencies.
Five people with HIV antibodies were excluded from the analysis.
 
Serologic Testing
 
Plasma samples were obtained from all subjects and stored at
 

 
20ºC. Their serologic status with regard to HBV core antibody,
IgM HBV core antibody, and hepatitis B surface antigen and the con-
centrations of antibody to hepatitis B surface antigen were deter-
mined by enzyme-linked immunosorbent assay (ELISA) according to
the manufacturer’s instructions (Boehringer–Mannheim, Munich,
Germany). HIV-antibody status was determined by ELISA (Wellco-
zyme, Wellcome, Beckenham, United Kingdom), with positive tests
confirmed by the Western blot assay.
 
MHC Typing
 
Class I serotyping was performed on lymphocytes, which were
available from about half the subjects in each group. Serologic MHC
class I types were determined by standard microlymphocytotoxicity
assays of fresh or cryopreserved cells, using 180 well-characterized
types of antiserum.
 
14
 
 MHC class II typing was performed by analysis
of restriction-fragment–length polymorphisms (RFLPs) as described
elsewhere, with the restriction enzymes 
 
Taq
 
I and 
 
Bam
 
HI.
 
14,15
 
 In this
assay, band patterns determined by Southern blot analysis corre-
spond to MHC class II haplotypes and are expressed as two numbers
separated by a hyphen (e.g., 13-2, 25-1). This analysis was supple-
mented, when necessary, by amplification by the polymerase chain
reaction and blotting with sequence-specific oligonucleotides.
 
14,15
 
 All
subjects were assigned an MHC class II type.
 
Statistical Analysis
 
The frequencies of MHC class I phenotypes and of RFLP-defined
class II haplotypes were compared between people who had recov-
ered from HBV infection and those with persistent infection with re-
gard to 23 MHC class I antigens and 10 class II haplotypes by the
chi-square test. When multiple comparisons are made concurrently,
apparently significant associations may arise by chance. To avoid
such errors, we first made multiple comparisons in the first group
(children), and then tested them in the second group (adults) with a
restricted hypothesis generated during the first stage of study.
 
16
 
 Rel-
ative risks, calculated from the crude odds ratios and given with 95
percent confidence intervals, reflect the likelihood of carrying a spe-
cific MHC type in the persistently infected group as compared with
the transiently infected group. The ethnic composition of the Gambia
is mixed, containing Mandinka (42 percent), Jola (14 percent), Wolof
(14 percent), and Fula (12 percent), as well as several less common
groups.
 
15
 
 Therefore, Mantel–Haenszel tests were performed to assess
a possible confounding effect of ethnic origin. Among the adults, con-
centrations of antibody to hepatitis B surface antigen were compared
between subjects with 
 
HLA-DRB1*1302
 
 and those without that allele,
by the unpaired t-test.
 
R
 
ESULTS
 
Of the 1344 children recruited, 891 were unexposed
and 453 (33.7 percent) were positive for HBV core an-
tibody. Of these, 185 (40.8 percent) were positive for
hepatitis B surface antigen and negative for IgM HBV
core antibody (i.e., they had persistent infection), and
218 (48.1 percent) were positive for IgG HBV core
antibody, negative for IgM HBV core antibody, and
negative for hepatitis B surface antigen (i.e., they had
transient infection). The remaining 50 children (11.0
percent) were excluded from the study because they
were positive for both hepatitis B surface antigen and
IgM HBV core antibody (i.e., they had recent infec-
tion). The increase in the carriage of HBV core anti-
body and hepatitis B surface antigen with age is shown
in Figure 1. Of the 260 adults, 25 were unexposed and
235 (90.4 percent) were positive for HBV core anti-
body. Of these, 40 (17.0 percent) had persistent infec-
tion, and 195 (82.9 percent) had transient infection.
The frequencies of MHC class I antigens and class II
haplotypes in the children are shown in Tables 1 and
2, respectively, and those in the adults are shown in Ta-
bles 1 and 3.
Possible associations between the MHC class I anti-
gens 
 
HLA-B50
 
 (relative risk, undefinable; 95 percent
confidence interval, 1.2 to 
 
∞
 
; P
 

 
0.015) and 
 
HLA-Cw1
 
(relative risk, 9.82; 95 percent confidence interval, 1.2
to 448; P
 

 
0.02) and persistent carriage of hepatitis B
surface antigen were suggested by the data from the
study of children (Table 1). These associations, howev-
er, were not supported by the data from the study of
adults (Table 1). Although none of the class I pheno-
types studied were associated with clearance of HBV,
the power of this study to detect class I associations
was lower than the power to detect class II associa-
tions, because only about half the subjects underwent
MHC class I typing, and class I antigens are more di-
verse than class II antigens in this population.
MHC class II haplotypes were initially determined
with the restriction enzyme 
 
Taq
 
I.
 
15
 
 The RFLP pattern
25-1, which corresponds to the class II haplotypes
 
DRB1*1302–DRB3*0301–DQA1*0102–DQB1*0501
(DRw13/DQw5) 
 
and
 
 DRB1*1302–DRB3*0301–
DQA1*0102–DQB1*0604 (DRw13/DQw6), 
 
was found in
58 of the 218 children with transient HBV infection
(26.6 percent) and in 30 of the 185 children with per-
sistent infection (16.2 percent) (relative risk, 0.53; 95
percent confidence interval, 0.32 to 0.90; P
 

 
0.012)
(Table 2). This pattern was associated with a protective
effect against persistent carriage of HBV. The RFLP
pattern 13-2, which corresponds to the class II haplo-
type 
 
DRB1*1301–DRB3*0101–DQA1*0103–DQB1*0603,
 
was also reduced in frequency in persistently infected
children (relative risk, 0.35; 95 percent confidence in-
terval, 0.1 to 1.0; P
 

 
0.037). No other haplotype stud-
ied showed a significant alteration in frequency.
We then analyzed these two possible associations in
the adult group.
 
 HLA-DRB1*1302
 
 was found in 50 of
195 adults with transient HBV infection (25.6 percent)
and 3 of 40 adults with persistent infection (7.5 per-
cent) (relative risk, 0.24; 95 percent confidence inter-
val, 0.04 to 0.80; P
 

 
0.012) (Table 3). After stratifica-
tion according to ethnic group, the Mantel–Haenszel
weighted relative risk was 0.23 (95 percent confidence
interval, 0.05 to 0.83; P
 

 
0.022), and the possibility of
a significant confounding effect of ethnic origin was
thereby excluded. The possible association with 
 
HLA-
DRB1*1301 
 
was neither confirmed nor excluded by the
data on adults. 
 
HLA-DRB1*1301
 
 was present in 1 of 40
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Figure 1. Increase in the Prevalence of Antibody against the
HBV Core Antigen and Changes in the Carriage of Hepatitis B
Surface Antigen with Age in the Gambia.
Mother-to-child transmission is not a major route of transmission
in this population. Carriage of hepatitis B surface antigen in
adults was lower than that in 10-year-old children, suggesting
that the elimination of HBV may often be completed during ado-
lescence. The number of subjects in each age group is shown
below the graph.
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adults with persistent infection and in 7 of 195 adults
with transient infection (odds ratio, 0.69; 95 percent
confidence interval, 0.02 to 5.62; P
 

 
1.0).
Children and adults with the RFLP pattern 25-1
were further subdivided according to whether they had
the 
 
DQw5 
 
or the 
 
DQw6
 
 allele. Relative risks and 95 per-
cent confidence intervals were calculated for the two
haplotypes (Table 4), and the elimination of HBV was
found to be associated with both. This indicates that
protection from persistent carriage of HBV was pri-
marily associated with HLA-DR rather than with the
HLA-DQ molecules encoded by the RFLP 25-1 pat-
tern, a localization that is important in analyzing the
molecular basis of this finding.
A possible confounding effect of variation in the
closely linked 
 
TNF
 
a
 
 gene promoter was analyzed.
Among these subjects, 
 
HLA-DRB1*1302
 
 and a 
 
TNF
 
a
 
promoter variant are in linkage disequilibrium.
 
17
 
 Strat-
ified analyses indicated that the effect of HLA-DR was
independent of the 
 
TNF
 
a
 
 gene polymorphism (data
not shown). In 25 adults with 
 
DRB1*1302
 
 (mean age,
28.6 years), the mean (
 

 
SD) concentration of antibody
to hepatitis B surface antigen was 15.5
 

 
41.5 IU per li-
ter. In 25 adults without 
 
DRB1*1302
 
 (mean age, 32.2
years), the mean concentration of antibody to hepatitis
B surface antigen was 22.3
 

 
48.5 (P
 

 
0.598).
 
D
 
ISCUSSION
 
We found an association between the RFLP-defined
MHC class II haplotype 25-1 and clearance of HBV
infection among groups of children and adults in the
Gambia. The 25-1 pattern represents two MHC
class II haplotypes, 
 
DRB1*1302–DRB3*0301–DQA1*
0102–DQB1*0501 
 
and
 
 DRB1*1302–DRB3*0301–
DQA1*0102–DQB1*0604.
 
 Further analysis showed that
both 
 
DRB1*1302 
 
haplotypes were associated with the
clearance of HBV; it is therefore probable that one or
both of the shared HLA-DR alleles are responsible for
this association. 
 
HLA
 
-
 
DRB1*1302
 
 is found only on the
25-1 RFLP pattern, whereas 
 
HLA-DRB3*0301
 
 is also
found on other RFLP-defined haplotypes in the Gam-
bia.
 
15
 
 Furthermore, the product of 
 
DRB1*1302
 
 is ex-
pressed at a higher level than the product of 
 
DRB3
 
 and
may thus be of greater functional importance, particu-
larly because T cells restricted by products of the 
 
DRB1
 
locus are identified more frequently than are 
 
DRB3
 
-re-
stricted T cells with regard to most antigens.
The RFLP pattern 13-2, which corresponds to the
c lass  II  haplotype 
 
DRB1*1301–DRB3*0101–
DQA1*0103–DQB1*0603,
 
 may also be associated with
resistance to persistent HBV infection, as suggested by
the data on persistently infected children. Interestingly,
the DRB1 allele of this haplotype, 
 
DRB1*1301,
 
 differs
from 
 
HLA-DRB1*1302
 
 by the substitution of a single
amino acid, a change of glycine (
 
*1302
 
) to valine
(
 
*1301
 
) at position 86 of the DR
 
b
 
 chain. Combining the
data on adults and children with RFLP pattern 13-2
gives a relative risk for persistent infection of 0.46 (95
percent confidence interval, 0.15 to 1.20; P
 

 
0.09). Our
data are therefore consistent with the hypothesis that
both 
 
DRB1*1302 
 
and
 
 DRB1*1301
 
 protect against per-
sistent HBV infection.
It is possible that RFLP pattern 25-1 is a marker for
a linked non–HLA-DR gene variant that confers pro-
tection against persistent HBV infection. We believe
 
*As determined by a standard microlymphocytotoxicity assay. Only antigens with frequen-
cies of 5 percent or more were analyzed.
†P
 

 
0.010.
‡Relative risk, 9.82 (95 percent confidence interval, 1.19 to 448.2); P
 

 
0.02.
 
Table 1. Frequencies of MHC Class I Antigens in Children and
Adults with Persistent or Transient HBV Infection.
 
MHC
A
 
NTIGEN
 
* C
 
HILDREN
 
A
 
DULTS
PERSISTENT 
INFECTION
 
(
 
N
 

 
64
 
)
 
TRANSIENT
INFECTION
 
(
 
N
 

 
81
 
)
 
PERSISTENT
INFECTION
 
(
 
N
 

 
14
 
)
 
TRANSIENT 
INFECTION
 
(
 
N
 

 
69
 
)
 
no. of subjects (% of group)
 
A1 9 (14.1) 11 (13.6) 1 (7.1) 13 (18.8)
A2 15 (23.4) 17 (21.0) 5 (35.7) 19 (27.5)
A3 4 (6.3) 7 (8.6) 0 5 (7.3)
A23 14 (21.9) 21 (25.9) 4 (28.6) 15 (21.7)
A26 12 (18.8) 13 (16.0) 3 (21.4) 8 (11.6)
A28 11 (17.2) 19 (23.5) 3 (21.4) 8 (11.6)
A30 17 (26.6) 19 (23.5) 4 (28.6) 15 (21.7)
A33 16 (25.0) 20 (24.7) 6 (42.9) 18 (26.1)
B7 9 (14.1) 11 (13.6) 4 (28.6) 9 (13.0)
B8 20 (31.3) 16 (19.8) 2 (14.3) 11 (15.9)
B17 12 (18.8) 14 (17.3) 2 (14.3) 14 (20.3)
B35 20 (31.3) 23 (28.4) 5 (35.7) 20 (29.0)
B50 5 (7.8) 0† 0 2 (2.9)
B53 9 (14.1) 15 (18.5) 5 (35.7) 17 (24.6)
B70 9 (14.1) 9 (11.1) 0 11 (15.9)
Cw1 7 (10.9) 1 (1.2)‡ 0 5 (7.3)
Cw2 9 (14.1) 4 (4.9) 0 17 (24.6)
Cw3 16 (25.0) 29 (35.8) 3 (21.4) 24 (34.8)
Cw4 13 (20.3) 26 (32.1) 6 (42.9) 20 (29.0)
Cw6 10 (15.6) 8 (9.9) 3 (21.4) 11 (15.9)
Cw7 12 (18.8) 19 (23.5) 4 (28.6) 9 (13.0)
Cw8 4 (6.3) 9 (11.1) 1 (7.1) 2 (2.9)
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association. Therefore, on RFLP pattern 25-1, HLA-
DRB1*1302 seems most likely to be associated with
protection against persistent HBV infection.
HLA-DRB1*1302 is also associated with a reduced
risk of severe malaria in Gambian children. This find-
ing may help to explain the high frequency of the
DRB1*1302–DRB3*0301–DQA1*0102–DQB1*0501 and
DRB1*1302–DRB3*0301–DQA1*0102–DQB1*0604 hap-
lotypes in this population.11 Malaria and HBV are both
important causes of premature death in West Africa.
Severe malaria has a high death rate in children under
the age of five years. Deaths from HBV infection usu-
ally occur in adults. It is therefore possible that there
is a selection advantage for the DRB1*1302 allele in the
Gambia associated with both HBV and malaria. 
Some children in West Africa carry hepatitis B sur-
face antigen for several years before HBV is eliminated
completely, and they may therefore have been misclas-
sified as long-term carriers. This phenomenon may ac-
count for the lower relative risk of carrying the 25-1
haplotype in adult men with persistent HBV carriage
as compared with children.
DRw6 — the serologic supertype of DRB1*1302 and
DRB1*1301 — was identified in two previous studies as
potentially protective against persistent HBV infection.
Van Hattum et al. found DRw6 nearly twice as often in
North European patients in whom HBV had cleared
than in those who had not eliminated the virus.9 In a
study of factors influencing the response of chronic
HBV infection to interferon therapy, we found that
DRw6 was associated with a favorable response.18
HLA-DRB1*1302 has been found in 10 to 26 percent of
Africans and African Americans, 4 to 11 percent of
whites, and 0 to 25 percent of Asians in large popula-
tion surveys.19 The association we have identified may
be relevant to other groups of people.
The activity of HBV-specific CD4 T-helper cells is
markedly reduced in patients with persistent infection
as compared with patients who have acute, self-limiting
infection.20 The responses of T-helper cells increase
during acute exacerbations of chronic HBV infection,
particularly at the time of seroconversion from hepati-
tis B e antigen to antibody to hepatitis B e antigen.21
Through its role in antigen presentation, the class II
molecule is critical to the development of T-helper–cell
responses. The variable ability of class II molecules to
present antigens may appear as variability in the re-
sponse of T-helper cells. In patients with persistent
HBV infection, failure to develop antibodies to hepatitis
B e antigen and surface antigen, and to develop suffi-
cient numbers of active HBV-specific cytotoxic T lym-
phocytes, may be related at least in part to the lack of
T-helper–cell response mediated by class II molecules
with relatively poor antigen-presenting ability. The
finding of equivalent levels of antibodies to the hepa-
titis B surface antigen in people with and without
DRB1*1302 suggests that the mechanism of the MHC
association is not mediated through the humoral re-
sponse to this antigen.
A protective effect against cervical carcinoma relat-
ed to the human papillomavirus has been reported that
*Relative risk, 0.35 (95 percent confidence interval, 0.1 to 1.0); P0.037.
†Relative risk, 0.53 (95 percent confidence interval, 0.31 to 0.90); P0.012.
Table 2. Frequencies of RFLP-Defined Class II Haplotypes in
Children with Persistent or Transient HBV Infection.
RFLP PATTERN DRB1 ALLELE DQ TYPE
PERSISTENT
INFECTION
(N  185)
TRANSIENT
INFECTION 
(N  218)
no. (%) of subjects
1-1 01 w5 14 (7.6) 17 (7.8)
4-4 04 w8 11 (5.9) 24 (11.0)
6-3 0301 w2 9 (4.9) 17 (3.2)
7-9 09 w2 26 (14.1) 32 (14.7)
8-5 08 w7 16 (8.6) 13 (6.0)
10-1 10 w5 33 (17.8) 33 (15.1)
13-2 1301 w6 5 (2.7) 16 (7.3)*
18-4 0302 w4 7 (3.8) 10 (4.6)
21-5 1304 w7 86 (46.5) 109 (50.0)
25-1 1302 w5/w6 30 (16.2) 58 (26.6)†
*Relative risk, 0.69 (95 percent confidence interval, 0.02 to 5.62); P1.0.
†Relative risk, 0.24 (95 percent confidence interval, 0.04 to 0.80); P0.012.
Table 3. Frequencies of RFLP-Defined Class II Haplotypes in
Adults with Persistent or Transient HBV Infection.
RFLP PATTERN DRB1 ALLELE DQ TYPE
PERSISTENT
INFECTION
(N  40)
TRANSIENT
INFECTION
(N  195)
no. (%) of subjects
1-1 01 w5 2 (5) 11 (5.6)
4-4 04 w8 2 (5) 19 (9.7)
6-3 0301 w2 1 (2.5) 7 (4.6)
7-9 09 w2 7 (17.5) 24 (12.3)
8-5 08 w7 4 (10) 9 (4.6)
10-1 10 w5 6 (15) 28 (14.4)
13-2 1301 w6 1 (2.5) 7 (3.6)*
18-4 0302 w4 4 (10) 6 (3.1)
21-5 1304 w7 21 (52.5) 80 (41)
25-1 1302 w5/w6 3 (7.5) 50 (25.6)†
*The RFLP-defined haplotype 25-1 represents two MHC class II haplotypes —
DRB1*1302–DRB3*0301–DQA1*0102–DQB1*0501 (DRw13/DQw5) and DRB1*1302–
DRB3*0301–DQA1*0102–DQB1*0604/05 (DRw13/DQw6). The 25-1 pattern was subdivided
by oligonucleotide probing and RFLP analysis into the DQ5 and DQ6 types, and the relative
risk was calculated for both. Because both haplotypes were associated with elimination of
HBV, we inferred that the DRB1*1302 allele was more likely than the DQ alleles to be respon-
sible for the association.
Table 4. Differential Analysis of the Relative Risk Associated with
Individual DRB1*1302 Haplotypes.*
POPULATION
AND DQ TYPE
PERSISTENT
INFECTION
TRANSIENT
INFECTION
RELATIVE RISK (95%
CONFIDENCE INTERVAL) P VALUE
no. of subjects
Children
DQ5
DQ6
22
12
34
26
0.73 (0.39–1.35)
0.51 (0.24–1.11)
0.28
0.06
Adults
DQ5
DQ6
3
0
34
18
0.38 (0.07–1.33)
0 (0–1.0)
0.12
0.05
that this is unlikely. On one side of HLA-DR lies the
TNFa promoter polymorphism, which is in strong link-
age disequilibrium with DRB1*1302 in this population
but is not associated with protection from persistent
HBV infection. On the other side of HLA-DR, the
HLA-DQ variants that were analyzed also showed no
The New England Journal of Medicine 
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is associated with DRB1*1302 and DRB1*1301.22 HBV,
Plasmodium falciparum, and the human papillomavirus
are complex microorganisms with many potential T-cell
epitopes that have different MHC restriction elements.
The MHC associations in these diseases suggest that
only a small number of immune responses may be of
particular importance for protection.
Recent advances in the study of peptides bound to
MHC class I and II molecules and the identification of
sequence motifs in bound peptides23,24 have facilitated
the analysis of the molecular basis of associations be-
tween MHC types and disease. Using this approach,
termed “reverse immunogenetics,” we have identified a
possible basis for the association of an MHC class I al-
lele, HLA-B53, with resistance to malaria in the Gam-
bia.25 Analysis of the association of HLA-DRB1*1302
with the clearance of HBV will be facilitated by the rel-
atively small size of the HBV genome and the availabil-
ity of its complete sequence. Recently, through the
analysis of individual peptides eluted from both HLA-
DRB1*1302 and HLA-DRB1*1301, we have identified
related peptide-binding motifs for these alleles (unpub-
lished data), allowing us to predict possible epitopes for
these class II molecules.
Our findings implicate variation in the genes govern-
ing the immune response of the host as one factor that
can explain the variable outcome of hepatitis B infec-
tion and offer an approach to elucidating the molecular
mechanisms of viral clearance. Further analysis of this
association may help identify strategies for the preven-
tion and management of chronic HBV infection.
We are indebted to Hilton Whittle for reviewing the data and mak-
ing valuable comments on the manuscript, to Estee Torok for assist-
ance with the serologic assays, and to N. Anstey, P. Twumasi,
D. Brewster, A. Hughes, L. Bayo, and L. Manneh for participating in
the collection of samples.
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